Sutro Biopharma, Inc. (STRO)
US — Healthcare Sector
Automate Your Wheel Strategy on STRO
With Tiblio's Option Bot, you can configure your own wheel strategy including STRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
STRO
Published: March 14, 2025 by: Benzinga
Sentiment: Negative
Published: March 14, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Read More
About Sutro Biopharma, Inc. (STRO)
- IPO Date 2018-09-27
- Website https://www.sutrobio.com
- Industry Biotechnology
- CEO Jane Chung
- Employees 269
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.